(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination - 2Party Urban areas of the World
- 3Find the Captivating Professional flowerbeds of the US
- 4Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- 5Thousands of Walgreens nasal spray bottles recalled. See which ones.
- The Best Business visionaries Under 30
- How did Ariana Grande get her Glinda voice? I’m the man behind the magic.
- This Tiny Neon Frog Dwells in the Clouds
- Poll: 62% of Americans would oppose U.S. military action in Greenland
- Geminid shooting stars: One of 2025's most exciting meteor showers begins tonight
- What is ‘Auld Lang Syne’? Why we sing this song at midnight on New Year’s Eve.
- Is Trump going to war with Venezuela?
- 15 Outrageous Cosplay Outfits That Will Blow You Away
- Help Your Efficiency with These Work area Updates
